| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Clinical Cancer Prevention [I. S., X. X., D. C., S. M. L.], Gastrointestinal Medical Oncology [I. S.], Biostatistics [J. S. M.], and Carcinogenesis [S. M. F.], and Division of Cancer Prevention [R. L.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030
In previous studies, we have found that expression of 15-lipoxygenase-1 (15-LOX-1) and its main product, 13-S-hydroxyoctadecadienoic acid, are decreased in human colorectal cancers and that nonsteroidal anti-inflammatory drugs (NSAIDs) can therapeutically induce 15-LOX-1 expression to trigger apoptosis in human colorectal cancer cells. NSAIDs similarly induce apoptosis in esophageal cancer cells, although the mechanisms of these effects remain to be defined. In the present study, we tested whether 15-LOX-1 is down-regulated in human esophageal cancers using paired normal and tumor human surgical samples and whether NSAIDs can up-regulate 15-LOX-1 to restore apoptosis in esophageal cancer cells. We found that: (a) 15-LOX-1 was down-regulated in human esophageal carcinomas; (b) NSAIDs induced 15-LOX-1 expression during apoptosis in esophageal cancer cells; and (c) 15-LOX-1 inhibition suppressed NSAID-induced apoptosis, which was restored by 13-S-hydroxyoctadecadienoic acid but not by its parent compound, linoleic acid. These findings demonstrate that 15-LOX-1 is down-regulated in human esophageal carcinomas and that NSAIDs induce apoptosis in esophageal cancer cells via up-regulation of 15-LOX-1. They also support the concept that the loss of the proapoptotic role of 15-LOX-1 in epithelial cancers is not limited to human colorectal cancers.
This article has been cited by other articles:
![]() |
X. Zuo, J. S. Morris, and I. Shureiqi Chromatin Modification Requirements for 15-Lipoxygenase-1 Transcriptional Reactivation in Colon Cancer Cells J. Biol. Chem., November 14, 2008; 283(46): 31341 - 31347. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zuo, L. Shen, J.-P. Issa, O. Moy, J. S. Morris, S. M. Lippman, and I. Shureiqi 15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation FASEB J, June 1, 2008; 22(6): 1981 - 1992. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Ciolino, C. J. MacDonald, O. S. Memon, S. E. Bass, and G. C. Yeh Sulindac regulates the aryl hydrocarbon receptor-mediated expression of Phase 1 metabolic enzymes in vivo and in vitro Carcinogenesis, August 1, 2006; 27(8): 1586 - 1592. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lippman and J. J. Lee Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res., March 15, 2006; 66(6): 2893 - 2903. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shureiqi, Y. Wu, D. Chen, X. L. Yang, B. Guan, J. S. Morris, P. Yang, R. A. Newman, R. Broaddus, S. R. Hamilton, et al. The Critical Role of 15-Lipoxygenase-1 in Colorectal Epithelial Cell Terminal Differentiation and Tumorigenesis Cancer Res., December 15, 2005; 65(24): 11486 - 11492. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Hsi, X. Xi, Y. Wu, and S. M. Lippman The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells Mol. Cancer Ther., November 1, 2005; 4(11): 1740 - 1746. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Y. Sun, N. Hail Jr, and R. Lotan Apoptosis as a Novel Target for Cancer Chemoprevention J Natl Cancer Inst, May 5, 2004; 96(9): 662 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Lovering, J. P. Ride, C. M. Bunce, J. C. Desmond, S. M. Cummings, and S. A. White Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin Cancer Res., March 1, 2004; 64(5): 1802 - 1810. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. ROMANO and J. CLARIA Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy FASEB J, November 1, 2003; 17(14): 1986 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wu, H. H. X. Xia, S. P. Tu, D. M. Fan, M. C. M. Lin, H. F. Kung, S. K. Lam, and B. C. Y. Wong 15-Lipoxygenase-1 mediates cyclooxygenase-2 inhibitor-induced apoptosis in gastric cancer Carcinogenesis, February 1, 2003; 24(2): 243 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Greenwald Cancer Prevention Clinical Trials J. Clin. Oncol., September 15, 2002; 20(90001): 14s - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shureiqi, W. Jiang, S. M. Fischer, X. Xu, D. Chen, J. J. Lee, R. Lotan, and S. M. Lippman GATA-6 Transcriptional Regulation of 15-Lipoxygenase-1 during NSAID-induced Apoptosis in Colorectal Cancer Cells Cancer Res., February 1, 2002; 62(4): 1178 - 1183. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Shureiqi and S. M. Lippman Lipoxygenase Modulation to Reverse Carcinogenesis Cancer Res., September 1, 2001; 61(17): 6307 - 6312. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |